Medtronic said revenue for fiscal 2024 Q3 (the quarter ended January 26, 2024) rose 4.7% as reported and 4.6% organically, to $8.089 billion. GAAP diluted EPS was $0.99, and non-GAAP diluted EPS was $1.30.

1. 01

   Medtronic said revenue for fiscal 2024 Q3 (the quarter ended January 26, 2024) rose 4.7% as reported and 4.6% organically, to $8.089 billion. GAAP diluted EPS was $0.99, and non-GAAP diluted EPS was $1.30.

2. 02

   The company raised its FY24 organic revenue growth outlook to 4.75% to 5% from the prior 4.75%, and raised its non-GAAP diluted EPS outlook to $5.19 to $5.21 from $5.13 to $5.19, the company said.

3. 03

   The company said on February 20, 2024 that it will exit the ventilator business and combine its remaining Patient Monitoring and Respiratory Interventions businesses. The Executive Vice President and President of the Medical Surgical Portfolio position will be eliminated, and Robert J. White will not remain with the company after April 26, 2024.

4. 04

   Medtronic reported free cash flow, calculated as net cash from operating activities less purchases of property, plant and equipment, of $2,849 million for the 9 months ended January 26, 2024, after operating cash flow of $4,010 million and capital expenditures of $1,161 million.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.